NCOA4 Antibody (monoclonal) (M05)
Mouse monoclonal antibody raised against a partial recombinant NCOA4.
|Application ||WB, IHC, IF, E|
|Calculated MW||69726 Da|
|Other Names||Nuclear receptor coactivator 4, NCoA-4, Androgen receptor coactivator 70 kDa protein, 70 kDa AR-activator, 70 kDa androgen receptor coactivator, Androgen receptor-associated protein of 70 kDa, Ret-activating protein ELE1, NCOA4, ARA70, ELE1, RFG|
|Target/Specificity||NCOA4 (NP_005428, 505 a.a. ~ 614 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||NCOA4 Antibody (monoclonal) (M05) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an androgen receptor coactivator. The encoded protein interacts with the androgen receptor in a ligand-dependent manner to enhance its transcriptional activity. Chromosomal translocations between this gene and the ret tyrosine kinase gene, also located on chromosome 10, have been associated with papillary thyroid carcinoma. Alternatively spliced transcript variants have been described. Pseudogenes are present on chromosomes 4, 5, 10, and 14.
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Sadow PM, et al. Endocr Pathol, 2010 Jun. PMID 20012784.The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. Landa I, et al. PLoS Genet, 2009 Sep. PMID 19730683.Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Richardson DS, et al. Cancer Res, 2009 Jun 1. PMID 19487296.Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. Lu Y, et al. J Lipid Res, 2008 Dec. PMID 18660489.Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Peng Y, et al. Am J Pathol, 2008 Jan. PMID 18156210.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.